Browse our collection of papers in
Astrazeneca (AZN)
C/F/766. Financial performance evaluation of Astra Zeneca
- WORDS:
- 1200
- DATE:
- 2010
- PRICE:
- 19.99 GBP
The paper looks at the financial performance of the UK pharmaceutical company Astra Zeneca during 2007-2008 presenting their ratio analysis and evaluating the company’s financial performance along the lies of their sales, profitability, etc.
KEYWORDS: Financial evaluation, ratio analysis, Astra Zeneca,
C/F/560. Strategic Financial Analysis of AstraZeneca and GlaxoSmithKline
- WORDS:
- 3100
- DATE:
- 2009
- PRICE:
- 39.99 GBP
The paper examines the factors that affected the financial performance of AstraZeneca (AZN) and GlaxoSmithKline (GSK) giving particular focus to the analysis of the product portfolio and recent developments in the pharmaceutical industry. An overview of the companies’ ratios over 2004-2008 is provided suggesting recommendations for the investors.
KEYWORDS: GlaxoSmithKline, GSK, AstraZeneca, AZN, pharmaceutical industry,
C/C/140. Feasibility Study: Digital Converter for Sales Force in AstraZeneca
- WORDS:
- 3500
- DATE:
- 2009
- PRICE:
- 39.99 GBP
The paper examines the feasibility of the automation of conversion of handwritten sales call data from the sales force of the pharmaceutical company AstraZeneca into digital formats. The company’s profile is presented arguing that information system (IS) development can create an effective and efficient sales force that is a source of competitive advantage.
KEYWORDS: AstraZeneca, Information system, Pharmaceutical, Sales Force,
C/F/278. AstraZeneca and GlaxoSmithKline share price performance valuation
- WORDS:
- 1300
- DATE:
- 2008
- PRICE:
- 19.99 GBP
The paper examines the factors that affected the share prices of AstraZeneca and GlaxoSmithKline, placing particular focus on the Company announcement published in the London Stock Exchange. A short overview of the company ratios is given suggesting recommendations for investors.
KEYWORDS: GlaxoSmithKline, AstraZeneca, pharmaceuticals,
C/B/587. AstraZeneca: Strategy Evaluation
- WORDS:
- 1400
- DATE:
- 2007
- PRICE:
- 19.99 GBP
AstraZeneca Plc, a leading global pharmaceutical company, specialises in cardiovascular, gastrointestinal, infection, neuroscience, oncological and respiratory therapies. AstraZeneca's key products such as Nexium, Seroquel, Crestor, Arimidex, and Symbicort achieved good sales growth for the third quarter of 2006 in a highly competitive drug making sector. Yet the Company's global sales ranks fourth behind GlaxoSmithKline, Sanofi-Aventis and Novartis. Issues raised in this report denotes a critical dimension that may weaken or strengthen AstraZeneca's position in taking advantage of the opportunities occurring and key developments expected in the pharmaceutical industry in five years from now.
KEYWORDS: AstraZeneca, Strategy, Pharmaceutical Industry, Drug Prescription Sector,
C/B/436. AstraZeneca: Strategic Analysis
- WORDS:
- 2500
- DATE:
- 2006
- PRICE:
- 29.99 GBP
The report provides a strategic analysis for one of the world's well known pharmaceutical companies, AstraZeneca. The report has been divided into three basic parts: external environment analysis, internal environment analysis and options development. The external environment analysis has been provided with the help of PEST, Industry Lifecycle and Porter's Five Forces analyses. The internal environment analysis has been provided by using value chain and hierarchy of resources of the company. The implications of these have been used to develop strategic options with the scenario planning process. The evaluations of these strategic options have also been provided by suitability, acceptability and feasibility indicators.
KEYWORDS: AstraZeneca, PEST, Porters Five Forces, Resources, Strategy, Scenario Planning,
P/F/470. Report on financial position of AstraZeneca
- WORDS:
- 4500
- DATE:
- 2006
- PRICE:
- 49.99 GBP
The paper reports on AstraZeneca (AZN), a UK based pharmaceutical company, describing the companys structure, reviewing their recent deals, and conducting analysis of the pharmaceutical industry, the trends in the industry benchmarks ratios, and the analysis of AstraZenecas income statements, balance sheets, cash flow statements, etc. The companys benchmark ratios are compared to those of their main rivals. Conclusions are made about whether AstraZeneca is a profitable investment.
KEYWORDS: AstraZeneca, pharmaceutical, benchmark ratios,
S/B/96. The Competitive Position Analysis & Competitive Strategy for AstraZeneca PLC
- WORDS:
- 2500
- DATE:
- 2005
- PRICE:
- 29.99 GBP
This paper examines the competitive position of AstraZeneca PLC, identifying the key environmental influences and the main drivers for change through the use of PESTEL and SWOT analyses, and the key competitive forces through the use of Porters 5 Forces. This paper then provides recommendations of the strategic options available to AstraZeneca.
KEYWORDS: competitive, position, competitive, strategy, astrazeneca, plc,
P/F/247. Share movements of the Astrazeneca (AZN) pharmaceutical company
- WORDS:
- 1000
- DATE:
- 2004
- PRICE:
- 19.99 GBP
The paper examines the performance of Astrazeneca (AZN), an Anglo/Swedish pharmaceutical company, on the London Stock Exchange (LSE). A point by point analysis of its major share movements over a year's period is given. Conclusions are made about the variables that make the sector more volatile than the average.
KEYWORDS: f, share, movements, astrazeneca, azn, pharmaceutical, company,
P/M/366. Organisational Behaviour of AstraZeneca
- WORDS:
- 1000
- DATE:
- 2004
- PRICE:
- 19.99 GBP
The paper investigates the features of organisational behaviour reporting on the pharmaceutical industry and using the performance of the AstraZeneca Company as an example. The structure of the industry is outlined. Passive and active modes of organisational behaviour at the company are discussed.
KEYWORDS: organisational, behaviour, astrazeneca,
S/B/63. MBA Dissertation. Strategic Analysis of the Merger of Astra AB and Zeneca PLC
- WORDS:
- 15000
- DATE:
- 2004
- PRICE:
- 159.99 GBP
This dissertation looks at the 1999, cross-border merger, of Sweden's Astra AB and the UK's Zeneca PLC to form AstraZeneca PLC. The paper asks the question ?What motivated two successful companies, Astra AB and Zeneca PLC, to merge and was the merger successful in terms of shareholder wealth?. It examines the merger by assessing each organisation prior to merger, the strategic process and cultural impact of merging, the financial and cultural organisation post merger, concluding with an assessment of success. The paper is thoroughly researched, presents an in-depth bibliography and uses a good range of analytical tools and models
KEYWORDS: mba, dissertation, strategic, merger, astra, ab, zeneca, plc,
Subject Catalogue
- Dissertations and Proposals
- Analysis of Companies
- Analysis of Industries
- Architecture, Design and Technology
- Computing and Mathematics
- E-Commerce and E-Business
- Economics
- Education
- Engineering
- Fashion and Culture
- Finance and Accounting
- General Business
- History
- Hospitality and Tourism
- Human Resource Management
- International Relations
- Law
- Literature, Language and Theatre Studies
- Management and Organisational Behaviour
- Marketing
- Media, Music and Art
- Operations Management
- Philosophy
- Politics
- Psychology
- Science, Medicine and Nursing
- Sociology
GET OUR GooGLE TOOLBAR BUTTON
BOOK MARK US
WHAT OTHERS HAVE SAID
I got the paper thanks it will come in very handy for my course thank you.Nicholas
